Trial Profile
Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Influence on Metabolic Abnormalities
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Lopinavir/ritonavir (Primary) ; Abacavir; Lamivudine; Lamivudine/zidovudine/abacavir; Non-nucleoside reverse transcriptase inhibitors
- Indications HIV infections
- Focus Adverse reactions
- 23 Aug 2011 New trial record